Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis

Bleomycin (BLM) induced lung injury is detectable in C57BL/6 mice using magnetic resonance imaging (MRI). We investigated the effects of the fibroblast activation protein (FAP) inhibitor, PT100, in this model. BLM (0.5mg/kg/day) was administered on days −7, −6, −5, −2, −1, 0 in the nostrils of male...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of pharmacology 2017-08, Vol.809, p.64-72
Hauptverfasser:	Egger, Christine, Cannet, Catherine, Gérard, Christelle, Suply, Thomas, Ksiazek, Iwona, Jarman, Elizabeth, Beckmann, Nicolau
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Bleomycin (BLM) Bleomycin - adverse effects Body Weight - drug effects Boronic Acids - pharmacology Boronic Acids - therapeutic use Dipeptides - pharmacology Dipeptides - therapeutic use Disease Models, Animal Fibroblast activation protein (FAP) Fibrosis Gelatinases - antagonists & inhibitors Gene Expression Regulation - drug effects Lung Magnetic Resonance Imaging Magnetic resonance imaging (MRI) Male Membrane Proteins - antagonists & inhibitors Mice, Inbred C57BL PT100 Pulmonary Fibrosis - diagnostic imaging Pulmonary Fibrosis - drug therapy Pulmonary Fibrosis - genetics Serine Endopeptidases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!